Giulia Marchetti
YOU?
Author Swipe
View article: Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study
Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study Open
Real-world experience supports the role of cefiderocol as a valuable option for GNBIs, with no clinical advantage of combination therapy over monotherapy. Notably, NDM-producing infections and use of cefiderocol as salvage therapy are asso…
View article: Vaccinations Included in the National Immunization Calendar as a Tool to Tackle Antimicrobial Resistance: Current Evidence for Selected Pathogens in Italy
Vaccinations Included in the National Immunization Calendar as a Tool to Tackle Antimicrobial Resistance: Current Evidence for Selected Pathogens in Italy Open
Background/Objectives: Antimicrobial (AMR) and antibiotic resistance (AR) remain major growing issues around the world. According to WHO, vaccinations play a strategic role in tackling AMR/AR; the new (upcoming) or existing vaccines (both …
View article: Implementation of infection prevention and control components in Italian hospitals based on a nationwide survey on behalf of INSIEME project
Implementation of infection prevention and control components in Italian hospitals based on a nationwide survey on behalf of INSIEME project Open
We aim to assess the state-of-the-art of Infection Prevention and Control (IPC) practices and their results in Italian healthcare facilities 6 years after the kick-off of the new National Plan for the Control of Antibiotic Resistance (PNCA…
View article: Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort Open
Objectives This analysis aimed to evaluate the rate of failure of first-line lamivudine/dolutegravir in a real-world setting and assess the effectiveness among people with HIV (PWH) at higher risk of suboptimal response. Methods The study …
View article: Incidence, risk factors and outcomes of healthcare-associated bacterial infections in COVID-19 patients receiving respiratory support: a retrospective cohort study
Incidence, risk factors and outcomes of healthcare-associated bacterial infections in COVID-19 patients receiving respiratory support: a retrospective cohort study Open
Bacterial HAIs are common in COVID-19 patients on respiratory support, especially in ICU settings, and are associated with increased mortality.
View article: Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry Open
Background This study aimed to clarify whether resistance detected in HIV-1 DNA might evolve in virologically suppressed highly treatment-experienced (HTE) individuals with multidrug resistance (MDR). Methods Twenty-three virologically sup…
View article: HIV Oral Pre-exposure Prophylaxis Effectiveness, Adherence, and Discontinuation in an Italian Multicentric Access Program: ItaPrEP Study
HIV Oral Pre-exposure Prophylaxis Effectiveness, Adherence, and Discontinuation in an Italian Multicentric Access Program: ItaPrEP Study Open
Background Italian oral pre-exposure prophylaxis (PrEP) implementation faced challenges until the drug reimbursement approval in 2023. National real-life data on effectiveness are lacking. This study aimed to report incidence rates (IR) of…
View article: All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry
All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry Open
People with human immunodeficiency virus (HIV) (PWH) with 4-drug class resistance (4DR) had a higher risk of death than non-4DR PWH, primarily due to lower CD4 cell counts. The priority for this vulnerable population is achieving virologic…
View article: The impact of COVID-19 hospitalizations on nursing home admissions: a regional insight into long-term care and public health
The impact of COVID-19 hospitalizations on nursing home admissions: a regional insight into long-term care and public health Open
Background To obtain the rate of admission to nursing homes (NHs) and to evaluate clinical characteristics and mortality rates of patients admitted to NHs after hospitalizations for COVID-19, compared to non-COVID-19 acutely hospitalized p…
View article: Investigating the Interplay of SARS-CoV-2 RNAemia and Peripheral Inflammation in Platelet Dysfunction During Acute SARS-CoV-2 Infection
Investigating the Interplay of SARS-CoV-2 RNAemia and Peripheral Inflammation in Platelet Dysfunction During Acute SARS-CoV-2 Infection Open
Background: Circulating degranulated platelets have been described during acute SARS-CoV-2 infection and associated with COVID-19 complications. This study investigated the relationship between the presence of plasma SARS-CoV-2 RNA (ie, SA…
View article: Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort Open
Background Phase 3 studies have shown long-acting (LA) cabotegravir/rilpivirine to be effective and tolerable as maintenance therapy in people with HIV (PWH). However, real-life data on their effectiveness are limited. Methods All PWH enro…
View article: Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data Open
The cancer risk of people with HIV (PWH) enrolled in the Italian COhort of Naives to Antiretrovirals (ICONA) with HIV diagnosis occurred between 01/1997 and 12/2023 has been compared to that of the corresponding general population of Italy…
View article: Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy Open
Objectives To estimate the incidence of comorbidities in persons with HIV (PWH) with a stable viral load (VL) of ≤50 copies/mL and evaluate the likelihood of treatment switch (TS) according to the new development of dyslipidaemia (DP), kid…
View article: Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection Open
In this study, we explored the link between gut impairment and severe COVID-19 in people with HIV (PWH). We compared PWH with COVID-19 to HIV-uninfected individuals hospitalized for the same condition. Despite more severe clinical symptoms…
View article: Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients
Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients Open
Background Anti-SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) have been shown to have clinical benefits in treating high-risk patients with mild-moderate COVID-19. SARS-CoV-2 RNA in serum (RNAemia), is usually associated with severe…
View article: Bacterial and Viral Coinfections in Adult Patients Hospitalized With COVID-19 Throughout the Pandemic: A Multinational Cohort Study in the EuCARE Project
Bacterial and Viral Coinfections in Adult Patients Hospitalized With COVID-19 Throughout the Pandemic: A Multinational Cohort Study in the EuCARE Project Open
Background Limited evidence exists on how bacterial and viral coinfections have developed since the SARS-CoV-2 Omicron variant emerged. We investigated whether community-onset coinfections in adult patients hospitalized with COVID-19 diffe…
View article: P11. Cefiderocol for Gram-negative infections: comparing monotherapy and combination therapy in the multicenter CEFI-BAC study
P11. Cefiderocol for Gram-negative infections: comparing monotherapy and combination therapy in the multicenter CEFI-BAC study Open
Background Real-life data on cefiderocol for Gram-negative infections remain limited. We aimed to evaluate factors associated with mortality in patients treated with cefiderocol either as monotherapy or combination therapy. Methods A retro…
View article: Switching from intravenous to oral antibiotic therapy in the treatment of infective endocarditis: a case series and literature review of real-world data
Switching from intravenous to oral antibiotic therapy in the treatment of infective endocarditis: a case series and literature review of real-world data Open
Background The POET trial, along with other studies, indicated that switching from IV to partial oral treatment (POT) in selected infective endocarditis (IE) cases is as effective as the traditional 4–6 weeks of IV therapy. This evidence s…
View article: Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort
Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort Open
B/F/TAF was generally well tolerated over 24 months, with high effectiveness and persistence observed among a broad range of people with HIV.
View article: P-831. Six Years Retrospective Study on <i>Staphylococcus aureus</i> Bacteremia: Impact of Persistance and COVID-19 Pandemic on 30-Days Mortality
P-831. Six Years Retrospective Study on <i>Staphylococcus aureus</i> Bacteremia: Impact of Persistance and COVID-19 Pandemic on 30-Days Mortality Open
Background S. aureus bacteremia (SAB) is characterized by high risk of complications and a high mortality. Persistent S. aureus bacteremia (P-SAB) has been associated with worse outcome. The COVID-19 pandemic might have further increased t…
View article: Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort Open
Background BICSTaR is a multi-national, observational cohort evaluating the effectiveness, safety, and patient-reported outcomes (PROs) in treatment-naïve (TN) and -experienced (TE) people with HIV-1 receiving bictegravir/emtricitabine/ten…
View article: Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC)
Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC) Open
Background The global mpox outbreak that started in May 2022 was caused by a novel clade IIb variant of the mpox virus (Orthopoxvirus monkeypox, MPXV). It differed from the traditional Western and Central Africa disease in transmission pat…
View article: Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry Open
Background Major adverse cardiovascular events (MACEs) may contribute to the high morbidity in people with four-class drug-resistant HIV (4DR-PWH). Objectives To explore the probability of MACEs in 4DR-PWH compared with non-4DR controls. M…